Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), a precision cardiovascular medicine company, has engaged IBN to support its corporate communications strategy. The company focuses on developing blood-based solutions for cardiovascular disease prevention and detection by integrating epigenetics, genetics, and artificial intelligence. This partnership comes as Cardio Diagnostics advances its clinical tests and data platforms designed to provide patient-specific insights.
The company's technology portfolio includes Epi+Gen CHD(TM), a prescription-only test that assesses three-year coronary heart disease risk. Other offerings are PrecisionCHD(TM) for detection and management, HeartRisk(TM) for population-level intelligence, and CardioInnovate360(TM) to support cardiovascular therapy development. These tools leverage molecular biomarkers combined with AI through the company's proprietary Artificial Intelligence-driven Integrated Genetic-Epigenetic Engine, known as Core Technology.
Cardio Diagnostics aims to make cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The engagement with IBN is expected to enhance the company's visibility as it seeks to become a leading medical technology company in this field. IBN operates through its BioMedWire brand, which specializes in communications for the biotechnology, biomedical sciences, and life sciences sectors.
BioMedWire provides access to wire solutions via https://ibn.fm/hFqWS, article syndication to over 5,000 outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. This comprehensive approach helps companies reach investors, influencers, consumers, journalists, and the general public. The latest news and updates relating to Cardio Diagnostics are available in the company's newsroom at https://ibn.fm/CDIO.
The implications of this partnership extend beyond corporate communications. For the healthcare industry, enhanced visibility for Cardio Diagnostics' AI-powered tests could accelerate adoption of precision medicine approaches to cardiovascular care. Cardiovascular disease remains a leading cause of death globally, and early detection through accessible blood tests represents a significant advancement in preventive healthcare. The company's focus on integrating multiple data types with artificial intelligence addresses the growing demand for personalized medicine solutions that can identify risk before symptoms appear.
For patients, the broader dissemination of information about these technologies could lead to increased awareness of advanced cardiovascular risk assessment options. The engagement with IBN's network may help educate both healthcare providers and the public about the availability of these precision medicine tools. As cardiovascular disease continues to impose substantial health and economic burdens worldwide, innovations in early detection and personalized management represent important steps toward reducing mortality and healthcare costs associated with heart conditions.
